Trial Profile

A clinical study of DAN-311 for the treatment of HER2-positive and HER2-low breast cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DAN-311 (Primary)
Indications HER2 positive breast cancer
Focus Adverse reactions

Most Recent Events

14 Dec 2022 New trial record
08 Dec 2022 According to a Dantari media release, the company expects to initiate this study in the second half of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com